The Valley Desk

NCT06312176 · Interventional trial

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Overall registry status Recruiting

Phase 3

Conditions Breast Neoplasms

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov